Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (4MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-527664
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.52766
Zusammenfassung
Cholangiocarcinoma (CCA) features a dismal prognosis with limited treatment options. Genomic studies have unveiled several promising targets in this disease, including fibroblast growth factor receptor (FGFR) fusions and isocitrate dehydrogenase (IDH) mutations. To fully harness the potential of genomically informed therapies in CCA, it is necessary to thoroughly characterize the available model ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags